

Dear

## FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing

Question:

1. Do you treat patients for urothelial cancer within your trust? (Yes/No) If No, to which trust(s) do you typically refer patients for treatment?

Answer:

Yes

Question:

2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
  - a. Atezolizumab (Tecentriq)
  - b. Avelumab (Bavencio)
  - c. Carboplatin single agent or in any other combination
  - d. Carboplatin with Gemcitabine
  - e. Carboplatin with Gemcitabine + Avelumab (Bavencio)
  - f. Carboplatin with Paclitaxel
  - g. Cisplatin single agent or in any other combination
  - h. Cisplatin with Gemcitabine
  - i. Cisplatin with Gemcitabine + Nivolumab (Opdivo)
  - j. Cisplatin with Gemcitabine + Avelumab (Bavencio)
  - k. Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev)
  - l. Nivolumab (Opdivo)
  - m. Pembrolizumab (Keytruda)
  - n. Other active systemic anti-cancer therapy
  - o. Palliative care only
  - p. Erdafitinib

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common  
name of Lothian Health Board*

- q. Cisplatin + Gemcitabine + Durvalumab (Imfinzi)
- r. BCG therapy
- s. Chemo-Radiation Therapy

Answer:

a.	0
b.	8
c.	7
d.	7
e.	0
f.	0
g.	9
h.	8
i.	0
j.	0
k.	0
l.	5<
m.	6
n.	5<
o.	linkage required*
p.	0
q.	0
r.	linkage required*
s.	5<

Question:

3. In the Metastatic urothelial cancer setting only, how many patients in the past 3 months were treated with the following systemic anti-cancer therapies first line approaches?
- a. Carboplatin single agent or in any other combination
  - b. Carboplatin with Gemcitabine
  - c. Carboplatin with Gemcitabine + Avelumab (Bavencio)
  - d. Carboplatin with Paclitaxel
  - e. Cisplatin single agent or in any other combination
  - f. Cisplatin with Gemcitabine
  - g. Cisplatin with Gemcitabine + Avelumab (Bavencio)
  - h. Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev)
  - i. Atezolizumab (Tecentriq) monotherapy
  - j. Palliative care only

k. Other

Answer:

a.	7
b.	7
c.	0
d.	0
e.	5<
f.	5<
g.	0
h.	0
i.	0
j.	requires linkage*
k.	14

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

\*Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.



If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive